Bryan Dechairo, Sherlock Biosciences CEO

Sher­lock, Feng Zhang's CRISPR di­ag­nos­tic out­fit, grabs $80M to go be­yond Covid-19

Af­ter spend­ing two years prov­ing its CRISPR and syn­thet­ic bi­ol­o­gy plat­forms could de­liv­er pow­er­ful Covid-19 di­ag­nos­tics, as well as ship­ping those test kits, Sher­lock Bio­sciences is ready to re­turn to — and tur­bocharge — its orig­i­nal mis­sion.

The Boston-based com­pa­ny has raised $80 mil­lion to de­vel­op a range of new tests that can be done on two in-house de­vices that can be used in an at-home set­ting.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.